PresentsADA TV

ADA TV 2020

WebsEdge/Health produced ADA TV covering the ADA 2020 Virtual Experience. Even though the conference didn't take place at a convention center ADA TV was still able to interview key speakers online and bring you all the up to date research and news on Diabetes.


Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy

Immune diseases like type 1 diabetes and multiple sclerosis can lead to severe complications in patients, yet there are currently very limited treatment options which mitigate their impact at best and no opportunity for a cure. However, the discovery of a new technology platform at Belgium’s KU Leuven Hospital offers new hope for these patients. Imotopes™ are modified HLA class II epitopes which block the immune processes that cause immune-mediated diseases, providing a potentially curative approach to severe chronic diseases. Imotopes™ induce cytolytic T cells that specifically eliminate antigen-presenting cells without affecting other functions of the immune system, intervening and stopping an autoimmune response at a time when attacked tissues can still regenerate. Imotopes™ is the product of Imcyse, a clinical-stage biopharmaceutical company based in Lieges, Belgium, pioneering the development of this new class of active, specific immunotherapies. This technology is most advanced in the area of Type 1 Diabetes, with the development of IMCY-0098. IMCY-0098 is a novel insulin-based Imotope™. In August 2019, Imcyse presented promising results from its first in human trial, a phase Ib safety study with IMCY-0098 in patients with early type 1 diabetes (T1D): IMCY-0098 is safe, well-tolerated, does not accelerate disease and is associated with immune modulation. Imcyse is working with top clinicians at KU Leuven, as well as being part of INNODIA, a global partnership to fight Type 1 Diabetes. Through INNODIA’s Patient Advisory Committee Imcyse will ensure they deliver the treatment that Type 1 Diabetes patients want and need. As clinical trials progress and basic research continues, the Imotope™ technology platform has the potential to address a wide range of indications in the vast field of immunology from diabetes to even less treatable conditions – with the potential to create a paradigm shift in the way these conditions are treated.


No comments yet... Be the first!

Post your comment:

Please read our comments policy before posting your comment. By pressing the "Submit Comment" button you agree to our privacy policy.
https://youtu.be/-fCiL0LnQV0 ADA TV Day 1 Highlights

ADA TV Day 1 Highlights


https://youtu.be/qvZjnhwJWY0 ADA TV Day 2 Highlights

ADA TV Day 2 Highlights


https://youtu.be/7CAgAjRIKkQ ADA TV Day 3 Highlights

ADA TV Day 3 Highlights


https://youtu.be/htn0Yb7qjcw ADA TV Day 4 Highlights

ADA TV Day 4 Highlights


https://youtu.be/kN76eMfjGbs ADA TV Day 5 Highlights

ADA TV Day 5 Highlights




Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy

https://youtu.be/xFQ-djoTMPc Digital Diagnostics

Digital Diagnostics

Forging a New Path: Healthcare AI Done the Right Way

https://youtu.be/uKwGE29m4mw vTv Therapeutics

vTv Therapeutics

Meeting Challenges in Type 1 Diabetes Management

https://youtu.be/X-GlkjboJ54 Arkansas Children's Hospital

Arkansas Children's Hospital

Focus Determining Reality: Diabetes in Arkansas

https://youtu.be/K0gbsnoJDDE William Polonsky, PhD

William Polonsky, PhD

Providing Hope to People with Diabetes

https://youtu.be/6E3KzperR1o Jiandie Lin, PhD

Jiandie Lin, PhD

Signalling Pathways in Diabetes and Obesity

https://youtu.be/1MEFxHoWXaA Introducing ADA's New Chief Scientific & Medical Officer

Introducing ADA's New Chief Scientific & Medical Officer

Robert M. Gabbay, MD, PhD

Mary De Groot, PhD

Mary De Groot, PhD

Diabetes Care During COVID-19

https://youtu.be/ao48Ds2w5Pc Ele Ferrannini, MD

Ele Ferrannini, MD

Breakthroughs in Insulin Resistance

https://youtu.be/lYSvfE8B-Lc Robert H. Eckel, MD

Robert H. Eckel, MD

Diabetes and the USA

https://youtu.be/rTVzuoOdxck Phase 3 Clinical Trials - Hua Medicine

Phase 3 Clinical Trials - Hua Medicine

COVID-19 in China